TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bioventus ( (BVS) ) has shared an update.
On November 14, 2025, Bioventus Inc. appointed Ajay Dhankhar, PhD, as a Class II director, effective immediately, with his term ending at the 2026 annual stockholders meeting. Dr. Dhankhar, who has extensive experience in corporate development and strategy within the healthcare sector, is the second designee of the S+N Stockholders to the Board, alongside Philip G. Cowdy. His appointment aligns with the Stockholders Agreement, which allows Smith & Nephew affiliates to designate directors based on their shareholding. Dr. Dhankhar will not receive compensation from the company for his role.
The most recent analyst rating on (BVS) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Bioventus stock, see the BVS Stock Forecast page.
Spark’s Take on BVS Stock
According to Spark, TipRanks’ AI Analyst, BVS is a Neutral.
Bioventus’s overall stock score is driven by strong earnings call performance and solid financial improvements, particularly in cash flow and debt reduction. However, valuation concerns due to a negative P/E ratio and lack of dividend yield, along with mixed technical indicators, temper the overall score.
To see Spark’s full report on BVS stock, click here.
More about Bioventus
Average Trading Volume: 337,259
Technical Sentiment Signal: Sell
Current Market Cap: $608.3M
For detailed information about BVS stock, go to TipRanks’ Stock Analysis page.